CIK 1703031
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 44.98% | 14 |
| Unclassified | 30.37% | 4 |
| Health Care Equipment & Supplies | 22.93% | 1 |
| Life Sciences Tools & Services | 1.73% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | HTFL | Heartflow, Inc. | Health Care | 22.93% |
| 2 | NAMS | NEWAMSTERDAM PHARMA COMPANY | Unclassified | 21.09% |
| 3 | OLMA | Olema Pharmaceuticals, Inc. | Health Care | 10.05% |
| 4 | SVRA | Savara Inc | Health Care | 8.67% |
| 5 | PHVS | PHARVARIS N V | Unclassified | 6.82% |
| 6 | SLDB | Solid Biosciences Inc. | Health Care | 6.37% |
| 7 | XFOR | X4 Pharmaceuticals, Inc | Health Care | 2.97% |
| 8 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 2.74% |
| 9 | ANNX | Annexon, Inc. | Health Care | 2.60% |
| 10 | KYTX | Kyverna Therapeutics, Inc. | Health Care | 2.42% |
16/20 names classified · sector 69.6% of weight · industry 69.6% · mkt cap 69.6%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 69.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 2% of book weight classified — the grid is NOT representative of the whole book.
Classified: 1.9% of book weight (1/20 names) · unclassified 98.1%: HTFL, NAMS, OLMA, SVRA, PHVS, SLDB, XFOR, DNTH, ANNX, KYTX +9 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | HTFLHEARTFLOW INC | 10,448,158 | $254M | 22.9% | TRIM −16% |
| 2 | NAMSNEWAMSTERDAM PHARMA COMPANY | 7,306,566 | $234M | 21.1% | HOLD |
| 3 | OLMAOLEMA PHARMACEUTICALS INC | 7,473,238 | $111M | 10.0% | TRIM −12% |
| 4 | SVRASAVARA INC | 17,600,621 | $96M | 8.7% | HOLD |
| 5 | PHVSPHARVARIS N V | 2,675,509 | $76M | 6.8% | TRIM −5% |
| 6 | SLDBSOLID BIOSCIENCES INC | 9,808,819 | $71M | 6.4% | ADD 24% |
| 7 | XFORX4 PHARMACEUTICALS INC | 7,967,454 | $33M | 3.0% | HOLD |
| 8 | DNTHDIANTHUS THERAPEUTICS INC | 362,470 | $30M | 2.7% | TRIM −51% |
| 9 | ANNXANNEXON INC | 5,212,674 | $29M | 2.6% | HOLD |
| 10 | KYTXKYVERNA THERAPEUTICS INC | 3,110,000 | $27M | 2.4% | HOLD |
| 11 | CABACABALETTA BIO INC | 9,677,125 | $26M | 2.3% | HOLD |
| 12 | CENTESSA PHARMACEUTICALS PLC | 635,000 | $25M | 2.3% | NEW |
| 13 | ALKSALKERMES PLC | 610,000 | $22M | 1.9% | NEW |
| 14 | RPIDRAPID MICRO BIOSYSTEMS INC | 8,434,560 | $19M | 1.7% | HOLD |
| 15 | CCCCC4 THERAPEUTICS INC | 7,171,910 | $19M | 1.7% | HOLD |
| 16 | AVIRATEA PHARMACEUTICALS INC | 2,360,638 | $13M | 1.1% | TRIM −5% |
| 17 | IRONDISC MEDICINE INC | 141,234 | $9M | 0.8% | NEW |
| 18 | UPBUPSTREAM BIO INC | 867,211 | $8M | 0.7% | TRIM −35% |
| 19 | XLOXILIO THERAPEUTICS INC | 664,021 | $6M | 0.5% | NEW |
| 20 | NAMSWNEWAMSTERDAM PHARMA CO NV-27 | 99,999 | $2M | 0.2% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| HTFLHEARTFLOW INC | — | — | — | 12.4M | 12.4M | 10.4M | $254M |
| NAMSNEWAMSTERDAM PHARMA COMPANY | 10.7M | 10.7M | 10.7M | 10.7M | 7.3M | 7.3M | $234M |
| OLMAOLEMA PHARMACEUTICALS INC | 7.5M | 6.8M | 6.8M | 6.8M | 8.5M | 7.5M | $111M |
| SVRASAVARA INC | 14.6M | 17.6M | 17.6M | 17.6M | 17.6M | 17.6M | $96M |
| PHVSPHARVARIS N V | 3.3M | 3.3M | 3.3M | 3.2M | 2.8M | 2.7M | $76M |
| SLDBSOLID BIOSCIENCES INC | 4.0M | 7.9M | 7.9M | 7.9M | 7.9M | 9.8M | $71M |
| XFORX4 PHARMACEUTICALS INC | — | — | 564K | 2.4M | 8.0M | 8.0M | $33M |
| DNTHDIANTHUS THERAPEUTICS INC | 2.7M | 2.7M | 2.5M | 1.3M | 744K | 362K | $30M |
| ANNXANNEXON INC | 5.2M | 5.2M | 5.2M | 5.2M | 5.2M | 5.2M | $29M |
| KYTXKYVERNA THERAPEUTICS INC | 3.4M | 3.4M | 3.4M | 3.4M | 3.1M | 3.1M | $27M |
| CABACABALETTA BIO INC | 2.8M | 2.8M | 9.7M | 9.7M | 9.7M | 9.7M | $26M |
| CENTESSA PHARMACEUTICALS PLC | — | — | — | — | — | 635K | $25M |
| ALKSALKERMES PLC | — | — | — | — | — | 610K | $22M |
| RPIDRAPID MICRO BIOSYSTEMS INC | 8.4M | 8.4M | 8.4M | 8.4M | 8.4M | 8.4M | $19M |
| CCCCC4 THERAPEUTICS INC | 1.1M | 1.1M | 1.1M | 1.1M | 7.2M | 7.2M | $19M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
